Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer takes on Astellas in purchase of experimental menopause relief

share with twitter share with LinkedIn share with facebook
08/11/2020 | 05:46am EDT

Bayer moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas.

Under the deal to buy KaNDy Therapeutics Ltd. from a group of investment firms, Bayer also agreed to pay up to $450 million (344 million pounds) for certain development achievements, with potentially more than $100 million additional sales-dependent payments, the German company said in a statement on Tuesday.

KaNDy in January announced positive data from the second of three phases of testing for NT-814, a new non-hormonal daily pill to ease hot flushes and night sweats, which Bayer said could generate peak annual sales of more then 1 billion euros (899 million pounds).

It is behind Japan's Astellas, which a year ago started the third phase of testing of a similar compound known as fezolinetant. NT-814, in turn, would address a wider range of symptoms, the head of Bayer's drugs division Stefan Oelrich told Reuters.

Bayer is seeking to revive its women's healthcare business as cheaper copied versions have lowered its sales of birth control pills.

It is close to settling injury claims over inserted birth control device Essure for more than 1 billion euros.

"We are one of the leaders in the area of women's health... resulting in synergies on many levels, starting with product development, but also commercialisation," Oelrich said.

Previous moves to reinvigorate the franchise include an alliance with Evotec to develop a treatment for a common cause of infertility in women.

Bayer's pharma unit, which in 2018 changed its strategy to increase its reliance on external sources of innovation, would not rule out future transactions larger than the KaNDy deal, Oelrich told Reuters.

But he cautioned that late-stage projects came at "very, very high prices".

By Ludwig Burger


Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.73% 1486.5 End-of-day quote.-20.51%
BAYER AG -1.60% 43.62 Delayed Quote.-40.09%
EVOTEC SE -1.03% 23.13 Delayed Quote.0.35%
share with twitter share with LinkedIn share with facebook
All news about ASTELLAS PHARMA INC.
09:33aASTELLAS PHARMA INC. : - New Roxadustat Data in Anemia of Chronic Kidney Disease..
AQ
10/16ASTELLAS PHARMA : to acquire iota Biosciences
AQ
10/15Nikkei flat as coronavirus resurgence in Europe hits sentiment
RE
10/15ASTELLAS PHARMA : FibroGen to Present New Efficacy and Safety Analyses from Roxa..
AQ
10/14ASTELLAS PHARMA : to Acquire iota Biosciences
BU
10/13ASTELLAS PHARMA : and Seagen Announce Positive Topline Results from Second Cohor..
AQ
10/09ASTELLAS PHARMA : and LabCentral Announce Golden Ticket Winners, Helping Emergin..
AQ
10/02ASTELLAS PHARMA : Celebrates First-Ever Virtual Day of Service to Help Non-Profi..
AQ
09/30ASTELLAS PHARMA : and MBC BioLabs Announce Golden Ticket Competition to Help Bio..
AQ
09/29ASTELLAS PHARMA : Real-World Evidence Studies Provide Further Insight into Negat..
AQ
More news
Financials
Sales 2021 1 274 B 12 087 M 12 087 M
Net income 2021 205 B 1 941 M 1 941 M
Net cash 2021 450 B 4 267 M 4 267 M
P/E ratio 2021 13,4x
Yield 2021 2,84%
Capitalization 2 761 B 26 155 M 26 196 M
EV / Sales 2021 1,81x
EV / Sales 2022 1,62x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 486,50 JPY
Spread / Highest target 81,6%
Spread / Average Target 53,0%
Spread / Lowest Target 14,4%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-20.51%26 377
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-4.31%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349